Vol.73 No.4 July 2025
Comparison of cefmetazole usage and changes in the susceptibility of Escherichia coli and Klebsiella pneumoniae to the drug over the years
Department of Pharmacy, Hirakata Kohsai Hospital, 1-2-1 Fujisaka Higashimachi, Hirakata, Osaka, Japan
Abstract
Cefmetazole (CMZ) has recently attracted attention for the treatment of infections caused by extended-spectrum β-lactamase (ESBL)-producing bacteria. On the other hand, acquisition of resistance due to excessive exposure to CMZ has been reported in vitro. In this study, we extracted data from the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) database from 2018 to 2023 to clarify the trends in CMZ usage at our hospital and the susceptibility rates of bacteria resistant to third-generation cephalosporins to the drug, focusing on Escherichia coli and Klebsiella pneumoniae; we compared the results with those of facilities that calculated additional healthcare reimbursement for infection prevention and control 1 ("Additional 1" facilities, total number of facilities, 269-1,010). The antimicrobial use density (AUD), days of therapy (DOTs), and AUD/DOT of CMZ at our hospital have been higher than the median for "Additional 1" facilities since 2020, but the susceptibility rate of E. coli did not differ from that in "Additional 1" facilities. However, a decrease in the susceptibility rate of third-generation cephalosporin-resistant K. pneumoniae, was observed from 2021-2023 in both hospitalized (73.8%) and outpatient (71.9%) cases.
Key word
cefmetazole, extended-spectrum β-lactamases, antimicrobial susceptibility, Escherichia coli, Klebsiella pneumoniae
Received
December 4, 2024
Accepted
April 7, 2025
Jpn. J. Chemother. 73 (4): 333-339, 2025
